Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Wilson on Long-term Data With Dabrafenib Plus Trametinib in Melanoma

July 27th 2017

Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses the long-term data with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF-mutant melanoma.

Amid Molecular Diagnostic Advances, IHC Retains Significance in Melanoma

July 25th 2017

Shane A. Meehan, MD, discusses the continued importance of IHC testing in melanoma, even with the emergence of novel molecular assays.

FDA Approves Ipilimumab for Pediatric Melanoma

July 24th 2017

The FDA has approved ipilimumab for the treatment of patients aged ≥12 years with unresectable or metastatic melanoma.

Expert Shares Optimism on Surgical Advances in Melanoma

July 24th 2017

Russell Berman, MD, discusses ongoing surgical advances in the treatment of melanoma.

Avelumab Recommended for EU Approval for Merkel Cell Carcinoma

July 21st 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of avelumab (Bavencio) for adults with metastatic Merkel cell carcinoma, according to Pfizer and Merck, the codevelopers of the PD-L1 inhibitor.

Surgical and Systemic Techniques Evolving for Melanoma Patients With Brain Mets

July 20th 2017

Douglas Kondziolka, MD, provides insight on some of the technical advancements in treating brain metastases in patients with melanoma.

Novel Therapy Partners Emerge in Melanoma Research

July 18th 2017

A novel combination therapy aimed at 2 processes implicated in NRAS-mutant melanoma has displayed promising activity in preclinical investigations, signaling an avenue of exploration for a new therapeutic approach for patients who currently have few options.

Unmet Needs in Kidney Cancer

July 17th 2017

Kidney Cancer: Non-Clear Cell Histology

July 17th 2017

Kidney Cancer: Vaccine-Based Approaches

July 17th 2017

Novel Combinations in Kidney Cancer

July 17th 2017

Anti-VEGF/Immunotherapy Combinations in Kidney Cancer

July 17th 2017

New Strategies in Kidney Cancer

July 17th 2017

Immunotherapy in Kidney Cancer

July 17th 2017

Practical Experience With Lenvatinib/Everolimus in RCC

July 17th 2017

mTOR/TKI Combination Therapy in Kidney Cancer

July 17th 2017

Role of mTOR Inhibition in Kidney Cancer

July 17th 2017

Frontline TKI Strategies in Kidney Cancer

July 17th 2017

Kidney Cancer: Continuing to Improve Survival

July 17th 2017

Understanding the Biology of Kidney Cancer

July 17th 2017

x